REGRANEX Gel is the only FDA-approved PDGF for the treatment of diabetic neuropathic ulcers, formulated to act as a first-line treatment following effective ulcer care.
The prevalence of diabetes is rising, with an estimated 15% of patients likely to experience a diabetic foot ulcer (DFU).1-3 85% of diabetes-related lower extremity amputations are preceded by a DFU4, yet it is estimated that 85% of those amputations can be prevented.3
